GUY BRANNON: Open Payments
NPI 1164481875 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,745 in 95 payments from 12 companies in 2025. Trend: 2023 $1,668 · 2024 $1,597 · 2025 $1,745
Food & beverage: $1,741Education: $5
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 19 | $274 |
| ABBVIE INC. | 11 | $208 |
| Otsuka America Pharmaceutical, Inc. | 10 | $195 |
| Janssen Pharmaceuticals, Inc | 10 | $186 |
| E.R. Squibb & Sons, L.L.C. | 10 | $158 |
| Lundbeck LLC | 6 | $128 |
| Alkermes, Inc. | 7 | $128 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $125 |
| LivaNova USA, Inc. | 3 | $118 |
| Teva Pharmaceuticals USA, Inc. | 5 | $99 |
Products named: INGREZZA, REXULTI, VRAYLAR, INVEGA SUSTENNA, COBENFY, ARISTADA, CAPLYTA, VNS THERAPY SYMMETRY MODEL 8103 GENERATOR.
Industry payments across LA — which companies pay providers there.
